Pore mutation in a G-protein-gated inwardly rectifying K+ channel subunit causes loss of K+-dependent inhibition in weaver hippocampus.
Weaver (wv) mice carry a point mutation in the pore region of a G-protein-gated inwardly rectifying K+ channel subunit (Kir3.2). wvKir3.2 conducts inward currents that may cause the loss of neurons in the cerebellum and substantia nigra. Although Kir3.2 is widely expressed in the CNS, significant morphological or physiological changes have not been reported for other brain areas. We studied the role of wvKir3.2 in hippocampal slices of young [postnatal day (P) 4-18] and adult wv/wv (>/=P24) mice, because protein levels of Kir 3. 1 and Kir3.2 appear to be normal in the first 3 postnatal weeks and only decrease thereafter. In disinhibited slices, the GABAB receptor agonist R-baclofen reduced burst activity in wv/wv mice but was much more potent in wild-type mice. Mean resting membrane potential, slope input resistance, and membrane time constant of CA3 neurons of adult wv/wv and wild-type mice were indistinguishable. However, R-baclofen or chloroadenosine did not induce K+ currents or any other conductance change in wv/wv mice. Moreover, electrical or chemical stimulation of inhibitory neurons did not evoke slow IPSPs in adult wv/wv mice. Only in a few cells of young wv/wv mice did GABAB receptor activation by R-baclofen or presynaptic stimulation induce small inward currents, which were likely caused by a Na+ ion influx through wvKir3.2 channels. The data show that the pore mutation in wvKir3.2 channels results in a hippocampal phenotype resembling Kir3.2-deficient mutants, although it is not associated with the occurrence of seizures.
Jarolimek
W
W
I.Physiologisches Institut, Universität Heidelberg, D-69120 Heidelberg, Germany.
Bäurle
J
J
Misgeld
U
U
D015762:2-Chloroadenosine / Q000494:pharmacology; D000367:Age Factors; D000818:Animals; D001418:Baclofen / Q000494:pharmacology; D004594:Electrophysiology; D005260:Female; D051676:G Protein-Coupled Inwardly-Rectifying Potassium Channels; D018755:GABA Agonists / Q000494:pharmacology; D058786:GABA-B Receptor Agonists; D019204:GTP-Binding Proteins / Q000378:metabolism; D006624:Hippocampus / Q000737:chemistry* / Q000502:physiology; D015640:Ion Channel Gating / Q000235:genetics*; D008024:Ligands; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008818:Mice, Neurologic Mutants; D009433:Neural Inhibition / Q000187:drug effects; D010507:Periodicity; D017354:Point Mutation; D011188:Potassium / Q000378:metabolism / Q000494:pharmacology*; D015221:Potassium Channels / Q000819:agonists / Q000235:genetics* / Q000378:metabolism; D024661:Potassium Channels, Inwardly Rectifying; D012701:Serotonin / Q000494:pharmacology; D013569:Synapses / Q000737:chemistry / Q000187:drug effects / Q000502:physiology
D051676:G Protein-Coupled Inwardly-Rectifying Potassium Channels; D018755:GABA Agonists; D058786:GABA-B Receptor Agonists; D008024:Ligands; D015221:Potassium Channels; D024661:Potassium Channels, Inwardly Rectifying; D015762:2-Chloroadenosine; D012701:Serotonin; D019204:GTP-Binding Proteins; D001418:Baclofen; D011188:Potassium